Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
IFNG 3458 GLUCOSAMINE CHEMBL606759 DrugBank 16431966, 16155294, 17238806, 16709188
IFNG 3458 APREMILAST CHEMBL514800 DrugBank
IFNG 3458 DOXIFLURIDINE CHEMBL1130 NCI 12553027
IFNG 3458 INTERFERON ALFA-2B CHEMBL1201558 NCI 10540707, 9192993
IFNG 3458 THEOPHYLLINE CHEMBL190 NCI 11918854
IFNG 3458 THROMBIN CHEMBL2108110 NCI 9731747
IFNG 3458 AMITRIPTYLINE CHEMBL629 NCI 10996474
IFNG 3458 MELPHALAN CHEMBL852 NCI 9864423
IFNG 3458 PEFLOXACIN CHEMBL267648 NCI 8673851
IFNG 3458 TRASTUZUMAB CHEMBL1201585 NCI 15297404
IFNG 3458 FUMARIC ACID CHEMBL503160 binder TTD
IFNG 3458 BLEOMYCIN (CHEMBL3039590) CHEMBL3039590 NCI 8556994
IFNG 3458 OLSALAZINE CHEMBL425 DrugBank 9797390, 17034586
IFNG 3458 FONTOLIZUMAB CHEMBL2108459 inhibitor, antibody TdgClinicalTrial, ChemblInteractions, DrugBank, TTD
IFNG 3458 TRETINOIN CHEMBL38 NCI 9792441
IFNG 3458 AMIKACIN CHEMBL177 NCI 8913387
IFNG 3458 METHYLPREDNISOLONE CHEMBL650 NCI 9396353
IFNG 3458 SURAMIN CHEMBL265502 NCI 1899122
IFNG 3458 CYCLOPHOSPHAMIDE CHEMBL88 NCI 10823419
IFNG 3458 GANCICLOVIR CHEMBL182 NCI 2992368
IFNG 3458 IBUPROFEN CHEMBL521 NCI 8931897
IFNG 3458 MELATONIN CHEMBL45 NCI 7722866
IFNG 3458 INTERLEUKIN 1BETA CHEMBL2074848 NCI 8383325
IFNG 3458 URSODIOL CHEMBL1551 NCI 10784002
IFNG 3458 PREDNISONE CHEMBL635 NCI 10784002

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
IFNG rs2430561 A glatiramer acetate efficacy no Allele A is not associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele T. 22111603 827823590
IFNG rs2069705 G Tumor necrosis factor alpha efficacy yes Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A. 26111149 1444929377
IFNG rs2430561 AA + AT Tumor necrosis factor alpha efficacy yes Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and CD cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation. Genotypes AA + AT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease and Inflammatory Bowel Diseases as compared to genotype TT. 24776844 1296666792